Posted on June 1, 2008 by crimsoncanary
Immunogen have presented Phase I data on its IGF-1R MAb AVE1642 as ASCO. The drug was found to be well tolerated when administered on its own and with docetaxel. Preliminary indicators of efficacy were also noted.
Filed under: kinase | Tagged: AVE-1642, AVE1642, IGF-1R, Immunogen, phase I, Sanofi-Aventis | 1 Comment »
Posted on June 1, 2008 by crimsoncanary
Arqule have presented results of Phase I trials of its c-Met Inhibitor ARQ 197 at ASCO. The compound was found to be safe and well tolerated
Filed under: kinase | Tagged: ARQ-197, ARQ197, ArQule, c-met, kinase, Met, phase I | Leave a Comment »
Posted on June 1, 2008 by crimsoncanary
Data presented at ASCO show Vectibix (panitumumab) in combination with FOLFOX is safe and shows efficacy in metastatic colorectal cancer
Filed under: kinase | Tagged: ABX-EGF, Amgen, EGF, panitumumab, phase iii, Vectibix | Leave a Comment »
Posted on June 1, 2008 by crimsoncanary
Exelixis’ MET/VEGFR2/RET inhibtor XL184 has been shown to be safe and to demonstrate efficacy in patients with advanced malignancies, especially Thyroid cancer.
Filed under: VEGF, kinase | Tagged: Exelixis, kinase, Met, RET, VEGFR2, XL-184, XL184 | Leave a Comment »
